Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies

Table 1 Baseline sleep impairment

Scale	ASTERIA I				ASTERIA II				GLACIAL
Scale	Placebo	Omalizumab 75 mg	Omalizumab 150 mg	Omalizumab 300 mg	Placebo	Omalizumab 75 mg	Omalizumab 150 mg	Omalizumab 300 mg	Placebo	Omalizumab 300 mg
MOS-Sleep Scale, SPI-II, n	80	77	80	81	79	82	82	79	83	252
Mean (SD)^a	47.8 (19.8)	48.4 (17.8)	49.2 (21.2)	47.4 (19.3)	47.4 (18.1)	48.0 (18.6)	48.5 (18.6)	47.8 (17.8)	47.9 (18.6)	49.1 (18.9)
UPDD Weekly Sleep Interference Score, n	80	77	80	81	79	82	82	79	83	252
Mean (SD)	12.6 (4.8)	12.2 (5.3)	12.1 (5.2)	12.2 (4.5)	12.1 (4.5)	11.8 (5.4)	11.4 (5.6)	11.6 (4.3)	11.2 (5.2)	11.9 (4.8)
CU-Q₂oL Sleep Problems domain, n	80	77	80	81	79	82	82	79	83	252
Mean (SD)^b	48.7 (23.6)	46.8 (22.7)	48.2 (25.2)	49.3 (22.9)	46.6 (19.9)	45.1 (22.6)	46.4 (23.7)	49.4 (21.1)	46.5 (21.8)	46.4 (21.5)

CU-Q ₂ oL Chronic Urticaria Quality of Life Questionnaire, MOS-Sleep Scale Medical Outcomes Study Sleep Scale, SPI-II Sleep Problem Index II, UPDD Urticaria Patient Daily Diary
^aNumber of patients: ASTERIA I: omalizumab 75 mg, n = 76; ASTERIA II: placebo, n = 78; GLACIAL: placebo, n = 82; omalizumab 300 mg, n = 250
^bNumber of patients: ASTERIA I: placebo, n = 63; omalizumab 75 mg, n = 59; omalizumab 150 mg, n = 63; omalizumab 300 mg, n = 61; ASTERIA II: placebo, n = 69; omalizumab 75 mg, n = 70; omalizumab 150 mg, n = 70; omalizumab 300 mg, n = 71; GLACIAL: placebo, n = 79; omalizumab 300 mg, n = 243